Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 8, 2006

Andrew von Eschenbach Voted Chief of FDA

  • The Senate voted Andrew von Eschenbach, M.D., chief of the FDA. Senators supported his nomination by a vote of 80 to 11. This decision comes after slightly over a year of Dr. von Eschenbach serving as acting head of the FDA. During that time he erased a major obstacle to his confirmation by allowing access to Plan B, the morning after pill, without a prescription.

    “It is critical that the FDA again be the gold standard of drug approval,” Senator Hillary Clinton in her official statement. “By making a long overdue decision on Plan B, Dr. von Eshenbach showed encouraging signs that he will take seriously the FDA’s responsibility to put science over ideology.  It is vitally important that Dr. von Eschenbach continue to put science first.”



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »